Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Vertex Pharmaceuticals (Australia) Pty Ltd,Elexacaftor/tezacaftor/ivacaftor and ivacaftor,"Cystic fibrosis, aged 2-5 years, with F508del mutation(s) in the CFTR gene, G551D mutation or other mutation responsive in vitro to Trikafta",Elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta),Options for investment,Community and Hospital,Respiratory System and Allergies
